Continued 5ASA use after initiation of anti‐TNF or immunomodulator confers no benefit in IBD: a population‐based study-Reference-Cited by-同舟云学术

Continued 5ASA use after initiation of anti‐TNF or immunomodulator confers no benefit in IBD: a population‐based study

Author:

Bernstein Charles N.¹²^ORCID,Tenakoon Aruni¹²,Singh Harminder¹²^ORCID,Targownik Laura E.³^ORCID

Affiliation:

1. Department of Internal Medicine Max Rady College of Medicine Rady Faculty of Health Sciences University of Manitoba Winnipeg MB Canada

2. University of Manitoba IBD Clinical and Research Centre Winnipeg MB Canada

3. Division of Gastroenterology Mount Sinai HospitalUniversity of Toronto Toronto ON Canada

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

Reference20 articles.

3. Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis;Feagan BG;Cochrane Database Syst Rev,2012

4. Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis;Sutherland L;Cochrane Database Syst Rev,2006

5. Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease;Akobeng AK;Cochrane Database Syst Rev,2016

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献